AI-generated research brief — verify at source
Biomarker Algorithm Misses Clinically Significant Prostate Cancers, Trial Halted Early
A randomised controlled trial in men aged 70 and older found that a plasma and urine biomarker-based triage algorithm detected clinically significant prostate cancers at a substantially lower rate than standard systematic biopsy — 26% versus 40% — a difference large enough to prompt early termination of the trial for futility. Although the algorithm reduced overall biopsy numbers, its failure to preserve sensitivity for aggressive disease represents a critical shortcoming that undermines its potential clinical utility in this population.
What Was Studied
Researchers investigated whether a multi-biomarker algorithm could safely replace systematic prostate biopsy in elderly men suspected of having prostate cancer, aiming to reduce unnecessary procedures without sacrificing detection of aggressive disease. This question is particularly relevant in older populations, where the harms of overdiagnosis and unnecessary biopsy must be carefully weighed against the risk of missing clinically significant cancers.
How It Was Studied
This was a prospective randomised controlled trial conducted across multiple centres, enrolling 202 men aged 70 years or older who had clinical suspicion of prostate cancer between October 2019 and September 2021. Participants were assigned in a 1:1 ratio to either an algorithm-triage arm or a standard systematic biopsy arm. The algorithm integrated a 10-gene mRNA expression panel derived from urine and plasma samples with clinical variables and PSA levels to predict the likelihood of International Society of Urological Pathology (ISUP) grade group 2 or higher cancer. Patient-reported quality of life was assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument at multiple time points over a 24-month follow-up period. The trial was terminated before reaching its planned sample size after an interim analysis demonstrated that the algorithm was not meeting pre-specified performance thresholds.
What Was Observed
- Clinically significant cancer detection was meaningfully lower in the algorithm arm. The biomarker triage identified clinically significant prostate cancer (ISUP grade group ≥ 2) in 26% of men, compared with 40% in the systematic biopsy arm — an absolute difference of approximately 14 percentage points (95% CI: −27.6 to −0.1 pp, P = 0.051). Although this narrowly missed conventional statistical significance, the magnitude of the gap was clinically concerning and contributed directly to the decision to halt the trial.
- The algorithm also reduced detection of indolent, lower-risk cancers. Fewer low-grade cancers were identified in the algorithm arm (7.9% vs. 19%), a statistically significant absolute reduction of roughly 11 percentage points (95% CI: −21.0 to −1.0 pp, P = 0.039). While avoiding overdiagnosis of indolent disease is a recognised goal, this benefit was outweighed by the concurrent loss of sensitivity for aggressive tumours.
- Quality of life outcomes were comparable between groups throughout follow-up. FACT-P total scores and all subdomain scores showed no statistically significant differences between the two arms at any point over 24 months (between-group differences ranging 0.1–2.2 points, all P > 0.05), indicating that neither approach conferred a measurable quality-of-life advantage over the other.
Why This Matters
The search for reliable non-invasive biomarker strategies to triage elderly men toward or away from prostate biopsy has been a major research priority, given the procedural risks and psychological burden associated with tissue sampling in older populations. This trial provides important negative evidence, demonstrating that a 10-gene mRNA panel integrated with clinical data did not perform adequately in this specific demographic. The early termination for futility adds weight to the null finding and signals that algorithmic approaches validated in younger or broader populations may not translate directly to elderly men without dedicated validation studies.
How to Read This Result
The trial’s early termination with only 202 participants limits statistical power, and the findings should be interpreted as evidence of algorithm underperformance in this specific population rather than a definitive verdict on all biomarker-based triage strategies for prostate cancer.
Limitations
The abstract does not explicitly report study limitations beyond early termination due to algorithm underperformance, which inherently reduced the trial’s statistical power and precluded full evaluation of secondary endpoints. The restricted sample size also limits the precision of effect estimates, as reflected in the wide confidence intervals observed for the primary cancer detection outcomes.